ANCA-positive Vaskulitiden nach Rituximabtherapie

March 2012, Volume 7, Issue 2, pp 151–154 | Cite as

Tubuläre Läsionen als Prediktor?

Für Sie gelesen

First Online: 16 February 2012

ANCA-associated glomerulonephritis after rituximab therapy

Do tubular lesions predict renal outcome?

This is a preview of subscription content, to check access.

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

1.
Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vaculitis. N Engl J Med 363:221–232PubMedCrossRefGoogle Scholar
2.
Jones RB, Cohen Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide for ANCA-associated renal vaculitis. N Engl J Med 363:211–220PubMedCrossRefGoogle Scholar
3.
Niles J (2011) Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vaculitis. Clin Exp Immunol 164(Suppl 1):27–30PubMedCrossRefGoogle Scholar
4.
Ntatsaki E, Mooney J, Watts RA (2011) ANCA vasculitis: time for change in treatment paradigm? Not yet. Rheumatology (Oxford) 50:1019–1024Google Scholar